Maspin is a unique serpin involved in the suppression of tumor growth and metastasis. To investigate whether increased levels of maspin protect against tumor progression in vivo, we established a transgenic model in which maspin is targeted to mammary epithelial cells by the Whey Acidic Protein (WAP) promoter for overexpression. We crossed these WAP-maspin transgenic mice with the WAP-TAg mouse model of tumor progression. Maspin overexpression increased the rate of apoptosis of both preneoplastic and carcinomatous mammary epithelial cells. Maspin reduced tumor growth through a combination of reduced angiogenesis and increased apoptosis. The number of pulmonary metastases was reduced in the presence of maspin overexpression. These data demonstrate that targeted overexpression of maspin can inhibit tumor progression in vivo, likely through a combination of increased apoptosis, decreased angiogenesis, and inhibition of tumor cell migration. Oncogene (2000) 19, 6053 ± 6058.
Introduction
Maspin is a unique member of the serpin (serine protease inhibitor) family whose downregulation is associated with the development of breast and prostate cancers (Hendrix, 2000; Pemberton et al., 1995; Sager et al., 1994; Seftor et al., 1998; Sheng et al., 1994; Zhang et al., 1997b) . Initially identi®ed from normal mammary epithelial cells, maspin has been shown to inhibit invasion and motility of mammary carcinoma cells in culture (Pemberton et al., 1997; Sager et al., 1996; Sheng et al., 1996; Sternlicht et al., 1997; Zhang et al., 1997c; Zou et al., 1994) . Its expression in normal cells is transcriptionally regulated and p53 can induce maspin expression in tumor cells (Domann et al., 2000; Zhang et al., 1997a, b; Zou et al., 2000) . Maspin expression is associated with better rate of survival and absence of metastasis in oral squamous cell carcinoma, indicating maspin might be a good prognostic marker for oral squamous cell carcinoma (Xia et al., 2000) . Furthermore, our laboratory has demonstrated recently that exogenous maspin inhibits endothelial cell motility and angiogenesis in an xenograft tumor model (Zhang et al., 2000) , suggesting that the tumor suppressor activity of maspin may depend on its ability to inhibit angiogenesis.
To characterize maspin's in vivo activity during tumor progression, we generated transgenic maspin mice exhibiting targeted overexpression of maspin to mammary epithelial cells under the control of mammary speci®c Whey Acidic Protein (WAP) promoter (Zhang et al., 1999) . Overexpression of maspin in normal mammary epithelial cells during pregnancy inhibits mammary gland development and induces apoptosis. WAP-maspin transgenic mice exhibit a reduced number of lobular alveolar structures during late pregnancy and impaired dierentiation. Apoptosis is increased in alveolar cells from transgenic mammary glands at midpregnancy without any changes in the rate of proliferation. These experiments demonstrate that maspin has potent biological activity on the growth and function of mammary epithelial cells in vivo. Since the primary goal of generating WAP-maspin transgenic mice was to test the protective role of maspin overexpression on mammary tumor progression, we crossed WAP-maspin transgenic mice with a strain of oncogenic WAP-Simian Virus (SV) 40 T antigen (TAg) mice. WAP-TAg transgenic mice develop mammary tumors with 100% frequency and can be utilized to examine speci®c mechanisms of tumor progression at both early and late time points (Li et al., 1996; Tzeng et al., 1993) . The SV40 TAg initiates tumorigenesis through the inactivation of both p53 and the pRb related family of proteins (Dyson et al., 1989; Li et al., 2000; Mietz et al., 1992) . In human breast cancers inactivation of p53 function is found in up to 40% of tumors , and mutations in Rb or related proteins have also been reported (Lee et al., 1988) . Here, we show that overexpression of maspin has a protective eect on mammary tumor progression and metastasis in vivo in the background of WAP-TAg induced tumors.
Results

Maspin overexpression increased the rate of apoptosis in preneoplastic mammary tissue
Maspin overexpression during pregnancy induces apoptosis of mammary epithelial cells, most likely by disrupting interactions between the mammary epithelial cells and the basement membrane (Zhang et al., 1999) . Dominant gain of TAg expression during pregnancy also induces apoptosis through a p53 independent mechanism (Li et al., 1996) . To determine if maspin Oncogene (2000) Figure 1 ). In addition, bitransgenic mice exhibited a signi®cant reduction in the number of alveolar-lobular structures and alveolar lumen size when compared to WAP-TAg single transgenic mice (Figure 1 ). Like WAP-TAg single transgenic mice, none of the WAP-maspin/WAP-TAg double transgenic mice could nurse their ospring beginning with the ®rst litters. These results demonstrate that overexpression of maspin can increase the rate of apoptosis in preneoplastic mammary gland.
Overexpression of maspin reduced tumor growth and vessel density, and increased apoptosis in primary adenocarcinomas
The rate of tumor growth was measured and compared in the presence and absence of maspin overexpression.
Tumors were measured bi-weekly after they were initially detected, and mice were euthanized when the primary tumor reached 2.5 cm in diameter. Because the tumor growth did not follow a linear curve, the tumor observation time (from the time of ®rst palpable tumor to the time when the tumor reached 2.5 cm in diameter) was used to assess the rate of tumor growth. The presence of maspin overexpression signi®cantly increased the time for a ®rst palpable tumor to reach 2.5 cm in diameter from 36.3 to 49.3 days (Table 2; P50.03).
To determine if maspin overexpression has an eect on microvessel density and apoptosis during tumor progression in vivo, microvessel density in adenocarcinomas with and without maspin overexpression were compared. Microvessel density was measured after CD31 staining. In small mammary tumors (tumor size 40.6 cm in diameter), the microvessel density was signi®cantly reduced (Table 3 ; P50.02), while the apoptotic index was signi®cantly increased in the presence of maspin overexpression (Table 3 ; P50.01).
To further characterize mammary tumor progression in the background of WAP-TAg mice, primary tumors were taken from both WAP-TAg and bitransgenic mice at dierent stages of tumor development. Tumor development underwent stages from hyperplasia and well-dierentiated tumor to poorly dierentiated tumors ( Figure 2 ). No signi®cant dierences in tumor histology were observed at any stages between these two groups of mice. One observation was that the mammary tumors developed in these mice were highly metastatic to lung. Other than typical pulmonary metastasis (Figure 2d ), the tumors were also present in bronchial air duct and blood vessel (Figure 2e, f) . No signi®cant histological dierences were observed between metastatic foci developed in WAP-TAg and bitransgenic mice. The Figure 1 Comparison of morphology and apoptotic pro®le of mammary gland at d17 of the ®rst pregnancy in control (a,d), WAPTAg (b,e), and bitransgenic mice (c,f). Tissues were sectioned and stained with H&E (a,b and c). In situ detection of apoptosis was performed (d,e and f). Photographs were at a magni®cation of 4006
TAg expression was followed by immunohistochemistry during tumor progression. Post-involution mammary epithelial cells had sporadic T-antigen staining in the nucleus, the number of TAg positive cells increased during tumor development (Figure 2g ). Nearly all cells in adenocarcinoma were TAg positive, and all tumors metastasized to lung retained the TAg positive staining pattern (Figure 2h,i) .
To quantitate the overexpression of maspin in bitransgenic mice, RNAse protection assay was carried out using RNAs isolated from tumor samples of both WAP-TAg and bitransgenic mice. Maspin expression level was signi®cantly higher in bitransgenic tumors than the level in WAP-TAg mice (Figure 3a,b; P50.02).
Maspin overexpression decreased the extent of pulmonary metastases but did not affect tumor initiation None of the TAg-/maspin+ and TAg-/maspin7 mice developed any tumors after 1 year observation. In a separate experiment, 25 WAP-maspin transgenic mice (C57BL/6 background) were followed for more than 2 years, none of the mice developed spontaneous mammary tumors. We compared the tumor incidences in WAP-TAg and bitransgenic mice. As shown in Figure 4 , both WAP-TAg and bitransgenic mice developed tumors at similar age. Within 24 weeks after they became pregnant, most of the WAP-TAg and bitransgenic mice developed mammary tumors. Thus, tumor initiation is TAg oncogene dependent. To detect lung tumor metastasis, lung tissues were sectioned for microscopic analysis. At the end point (all mice were sacri®ced when primary tumor reached about 2.5 cm in diameter), bitransgenic mice did not show any dierence from WAP-TAg mice in the number and weight of mammary tumors developed (data not shown). Three serial sections, each separated 300 mm from the other, were selected to score for micrometastatic tumor foci under high power microscope. As shown in Table 2 , 15 out of 26 (55.6%) WAP-TAg mice developed lung metastasis while in bitransgenic mice the rate of metastasis, was greatly reduced to 37.5% (15 out of 40 bitransgenic mice). To compare the dierence in the number of tumor foci of lung samples between these two species, the microscopic images of lung sections were captured and the foci number/lung area was quantitated for each mouse. The bitransgenic mice had decreased foci numbers (0.356 /10 4 pixels) compared to that of WAP-TAg mice (0.655 /10 4 pixels).
Discussion
Tumor metastasis involves multiple steps, including intravasation, extravasation and secondary site growth. We have studied maspin's role in tumor progression and metastasis by crossing WAP-maspin transgenic mice with WAP-TAg oncogenic mice. WAP-TAg transgenic mice model possesses speci®c features of some human breast cancers including the inactivation of p53 and pRb. Our study has completed a rather large survey of 66 mice, demonstrating that TAg model is highly metastatic to lung, with a frequency between 37.5 and 56.7%. This information should be useful for future metastasis study. Our data demonstrate that overexpression of maspin through a transgenic approach can partially block tumor progression, First, bitransgenic maspin/TAg mammary tumors grew considerably slower than their TAg controls (39% dierence, Table 2 ). Growth inhibition appeared secondary to an increase in apoptosis and a reduction in vescular density. Maspin overexpression increases apoptosis of both normal mammary epithelial cells during pregnancy and malignant breast cancer cells. The underlying mechanism is not completely understood. However, one possibility is that maspin overexpression alters the integrin pro®le in epithelial cells to induce apoptosis. Transgenic expression of a dominant negative b1 integrin in the mammary gland, which disrupted the function of b1 and its associated integrins, also results in a phenotype similar to that was observed in the WAP-maspin transgenic mice (Faraldo et al., 1998) . In addition, exogenous maspin modi®es cell attachment to ®bronec-tion by regulating integrin pro®les, including downregulation of b1 integrin (Seftor et al., 1998) . A second possibility is that the secreted maspin may directly decrease the number of microvessels in the mammary gland thus inducing apoptosis of mammary cells. Similarly, in the adenocarcinomas it is possible that the increased apoptosis is due to the fact that secreted maspin can block angiogenesis, thus increasing tumor cell apoptosis by decreasing the density of vascular vessels. This hypothesis is supported by a previous study in which xenograft tumor vessels and growth rate were both blocked by exogenous maspin (Zhang et al., 2000) .
This study also indicated that overexpression of maspin greatly reduced tumor metastasis to lung. This ®nding is in line with a recent report that increased levels of maspin is associated with better survival and A B Figure 3 RNase protection assay of the total maspin RNA in WAP-TAg and bitransgenic mammary tumors. (a) RPA assay was carried out using 5 mg RNAs from WAP-TAg (lanes 1 ± 5) and bitransgenic (lanes 6 ± 15) tumors. The RNAs were hybridized to both maspin and actin riboprobes and the gel was exposed to X-ray ®lm. (b) Quantitation of protected bands of maspin and actin by phosphoimaging analysis. The relative RNA level of maspin was calculated by dividing the volume of maspin band by that of actin. The dierence was calculated by student t-test. P50.02 indicated that levels of maspin in bitransgenic tumors were signi®cantly higher than that in WAP-TAg tumors Figure 4 Tumor free curves for WAP-TAg and WAP-TAg/ WAP-maspin bitransgenic mice. All female mice were mated at the age of 8 weeks. Age indicates the time period from the date of ®rst pregnant day 10 to the date of tumor appearance. No signi®cant dierence was observed in the rate of tumor initiation for these two groups of mice decreased lymph node metastases in oral squamous cell carcinoma (SCC) (Xia et al., 2000) . Maspin levels are down regulated during SCC tumor progression. Among the 44 SCC specimen surveyed, 10 samples with node metastasis had very low levels of maspin expression. None of the specimen with higher levels of maspin expression had any detectable node metastasis. In the study presented here, the increased maspin levels in the bitransgenic mice were associated with a 39% decrease in metastasis incidence. In contrast if maspin had no eect on metastasis, bitransgenic mice should have similar or increased incidence of metastases since they were observed for longer periods than the single WAP-TAg transgenic mice. The mechanism underlying the inhibition may be complicated. One possibility is that maspin blocks tumor cell migration and invasion. In vitro cell culture experiments have demonstrated that maspin is a very eective inhibitor against both breast and prostate tumor cell migration . Alternatively, maspin may directly block tumor angiogenesis (Zhang et al., 2000) , a key step in the process of metastasis.
Transgene overexpression of maspin does not completely block tumor progression and metastasis. This is because tumor progression lies on a balance between positive (oncogenic) and negative (tumor suppressive) factors. TAg is a very potent oncogenic factor since it inactivates two tumor suppressor genes (p53 and Rb). Even with expression of maspin in tumors (Figure 3 ), SV40 TAg expression can lead to accumulated mutations that can override maspin's protective eects. Moreover, a recent publication indicates that p53 itself is involved in the transcriptional activation of maspin by binding to its promoter (Zou et al., 2000) . With p53 being inactivated in TAg mice, it is possible less maspin will be expressed which shifts the balance more towards tumorigenesis. In order to counteract such a potent oncogenic eect, one may need to increase the level of maspin expression in tumors by either systemic delivery of maspin or by placing maspin transgene under the control of a stronger promoter. Such approaches are currently underway in our laboratory.
Materials and methods
Mice, mammary gland biopsies, and tumor progression studies WAP-maspin female mice (C57BL/6) were bred with WAPTAg male mice (NMRI) to generate four groups of mice on a mixed background of C57BL/6/NMRI: bitransgenic WAPmaspin/WAP-TAg, single transgenic WAP-TAg, single transgenic WAP-maspin, and non-transgenic mice. DNA PCR analysis of tail DNA was used to genotype mice as described previously for WAP-maspin (Zhang et al., 1999) and WAP-TAg transgenic mice (Li et al., 1996) . When 8 weeks old, female mice were bred to induce a ®rst pregnancy. Timed pregnancy were determined by plug appearance and con®rmed by delivery. At day 17 ®rst pregnancy mammary gland biopsies were performed to remove either the left or right #4 inguinal mammary gland. Mice from four groups were serially bred and followed for ®rst palpable tumor by examination at bi-weekly intervals. Tumor growth rate was measured by bi-weekly caliper measurement of tumor volume until the primary palpable tumor reached 2.5 cm in diameter. All mice were euthanized when the primary tumor reached 2.5 cm in diameter. Forty double transgenic WAP-maspin/WAP-TAg, 26 single transgenic WAP-TAg, 16 single transgenic WAP-maspin, and 19 non-transgenic female mice were used in the study. All females were continuously bred so that they underwent multiple cycles of pregnancy and parturition. Tumor sizes for 15 WAP-TAg and 27 bitransgenic mice were carefully measured bi-weekly using a caliper and recorded. Tumor volume was calculated using a formula: length6width 2 /2 (Tsujii et al., 1998) . Lung tissues from total 66 mice (26 WAP-TAg and 40 bitransgenic mice) were collected at the time of euthanasia. Fixed lung tissues were cut into 5 mm sections with each section separated from the next one by 50 mm. A total of 11 sections were collected for each lung. The three sections separated by 300 mm (section 1, 6 and 11) were stained with hematoxylin/eosin and examined for the presence of metastases. The other sections were used for TAg immunostaining. Lung metastases were quanti®ed by ®rst capturing microscopic images of the three H&E stained sections with a digital camera. The images were processed utilizing NIH Image software and the image size (pixels) for each lung sample was calculated. The volume of pulmonary metastases was expressed as the number of tumor foci per area of 10 4 pixels.
Ribonuclease protection assay
For ribonuclease protection assays (RPA), total RNA was isolated from tumor samples of WAP-TAg and WAPmaspin/WAP-TAg bitransgenic mice.
32
P-labeled antisense probes were generated by transcription of either a mouse maspin cDNA template (400 bp) or an actin control template (200 bp) under the T7 promoter using a kit (Promega, Inc., WI, USA) in accordance with the manufacturer's instruction. Total RNA (5 mg each lane) was subjected to RPA using an Ambion RPA III kit (catalog 1414). Approximately 1610 5 counts per minute (c.p.m.) of the maspin probe and 1610 3 c.p.m. of the actin probe were used per sample reaction. Protected bands were either exposed to an X-ray ®lm or quanti®ed by phosphoimaging analysis. Relative maspin RNA levels were obtained by dividing the quantitated volume of the protected maspin band by the volume of the actin control.
Histology, immunohistochemistry and in situ detection of apoptosis
Mammary tissues and tumors were ®xed in 10% neutral formalin buer, embedded in paran, and sectioned at 5 mm. SV40 TAg expression was evaluated by immunostaining. Tissue sections were treated with proteinase K (10 mg/ml) for 10 min at 378C and quenched with 0.03% of H 2 O 2 in PBS for 30 min at room temperature. The slides were blocked with 10% normal horse serum for 1 h before they were treated with the primary antibody. Anti-TAg monoclonal antibody (Pab101, Santa Cruz, CA, USA) was used in 1 : 1000 dilution at room temperature for 2 h. The secondary antibody (goat-antimouse IgG2a, Santa Cruz, CA, USA) was used at a dilution of 1 : 400 at room temperature for 1 h. Slides were then rinsed and incubated with an avidin-biotinperoxidase complex (ABC kit, Vector Laboratories, CA, USA), followed by DAB color development. Apoptotic cells were identi®ed by TUNEL assay utilizing a TDT nick endlabeling kit from Boehringer Mannheim following manufacturer's directions (Boehringer Mannheim, Inc., Germany). The percentage of mammary epithelial cells undergoing apoptosis in each mammary gland during ®rst pregnancy was determined by counting the number of apoptotic cells within a population of at least 1000 mammary epithelial cells. The number of mammary cancer cells undergoing apoptosis in the adenocarcinomas was determined by counting the number of apoptotic cells per 2006®eld. Three 2006®elds were counted for each tumor sample and the numbers were averaged. For CD31 staining, anti-CD31 monoclonal antibody (PharMingen, CA, USA) was used at 1 : 50 dilution at 48C overnight. Slides were then rinsed and incubated with an avidin-biotin-peroxidase complex (ABC kit, Vector Laboratories, CA, USA), followed by DAB color development. Tumor vessels were counted as described (Obermair et al., 1997) by ®rst scanning the sections at the low power for`hot' spots or high vascular density (406), and then counting the areas of microvessels at high power (2006) . MVD (microvessel density) was calculated by averaging the numbers from three`hot spot' ®elds with a 2006objective.
Statistical analyses
Dierences between groups were compared using the student t-test. A P value 50.05 was considered as signi®cant.
